BETNOVATE Betamethasone Valerate 1mg / mL Lotion 20mL
RXDRUG-DR-X1716
Discreet Packaging
FDA-registered Products
FDA-licensed Pharmacies
Indications/Uses
Betnovate is a potent topical corticosteroid indicated for adults, elderly and children >1 year for the relief of inflammatory and pruritic manifestations of steriod responsive dermatoses. These include atopic dermatitis (including infantile atopic dermatitis), nummular dermatitis (discoid eczema), prurigo nodularis, psoriasis (excluding widespread plague psoriasis), lichen simplex chronicus (neurodermatitis) and lichen planus, seborrhoeic dermatitis, irritant or allergic contact dermatitis, discoid lupus erythomatosus, adjunct to systemic steroid therapy in generalized erythroderma, insect bite reactions and miliaria (prickly heat).
Dosage/Direction for Use
Adults, Elderly and Children >1 year: Lotions: For treatment of hairy areas or when a minimal application to a large area is required.
Creams: For moist or weeping surfaces.
Ointments: For dry, lichenified or scaly lesions.
Apply thinly and gently rub in using only enough to cover the entire affected area once or twice daily for up to 4 weeks until improvement occurs, then reduce the frequency of application or change the treatment to a less potent preparation. Allow adequate time for absorption after each application before applying an emollient.
In the more resistant lesions eg, the thickened plaques of psoriasis on elbows and knees, the effect of Betnovate can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response in such lesions; thereafter, improvement can usually be maintained by regular application without occlusion.
If the condition worsens or does not improve within 2-4 weeks, treatment and diagnosis should be re-evaluated.
Atopic Dermatitis (Eczema): Therapy with Betnovate should be gradually discontinued once control is achieved and an emollient continued as maintenance therapy. Rebound of preexisting dermatoses can occur with abrupt discontinuation of Betnovate.
Recalcitrant Dermatoses: Patients Who Frequently Relapse: Once an acute episode has been treated effectively with a continuous course of topical corticosteroid, intermittent dosing (once daily, twice weekly, without occlusion) may be considered. This has been shown to be helpful in reducing the frequency of relapse.
Application should be continued to all previously affected sites or to known sites of potential relapse. This regimen should be combined with routine daily use of emollients. The condition and the benefits and risks of continued treatment must be re-evaluated on a regular basis.
Children: Betnovate is contraindicated in children <1 year. They are more likely to develop local and systemic side effects of topical corticosteroids and in general, require shorter courses and less potent agents than adults.
Care should be taken when using Betnovate to ensure the amount applied is the minimum that provides therapeutic benefit.
Elderly: Clinical studies have not identified differences in responses between the elderly and younger patients. The greater frequency of decreased hepatic or renal function in the elderly may delay elimination if systemic absorption occurs. Therefore, the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.
Renal and Hepatic Impairment: In case of systemic absorption (when application is over a large surface area for a prolonged period) metabolism and elimination may be delayed therefore increasing the risk of systemic toxicity. Therefore, the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.
Administration: Due to inflammable nature of Betnovate lotion, patients should avoid smoking or being near an open flame during application and immediately after use.
Creams: For moist or weeping surfaces.
Ointments: For dry, lichenified or scaly lesions.
Apply thinly and gently rub in using only enough to cover the entire affected area once or twice daily for up to 4 weeks until improvement occurs, then reduce the frequency of application or change the treatment to a less potent preparation. Allow adequate time for absorption after each application before applying an emollient.
In the more resistant lesions eg, the thickened plaques of psoriasis on elbows and knees, the effect of Betnovate can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response in such lesions; thereafter, improvement can usually be maintained by regular application without occlusion.
If the condition worsens or does not improve within 2-4 weeks, treatment and diagnosis should be re-evaluated.
Atopic Dermatitis (Eczema): Therapy with Betnovate should be gradually discontinued once control is achieved and an emollient continued as maintenance therapy. Rebound of preexisting dermatoses can occur with abrupt discontinuation of Betnovate.
Recalcitrant Dermatoses: Patients Who Frequently Relapse: Once an acute episode has been treated effectively with a continuous course of topical corticosteroid, intermittent dosing (once daily, twice weekly, without occlusion) may be considered. This has been shown to be helpful in reducing the frequency of relapse.
Application should be continued to all previously affected sites or to known sites of potential relapse. This regimen should be combined with routine daily use of emollients. The condition and the benefits and risks of continued treatment must be re-evaluated on a regular basis.
Children: Betnovate is contraindicated in children <1 year. They are more likely to develop local and systemic side effects of topical corticosteroids and in general, require shorter courses and less potent agents than adults.
Care should be taken when using Betnovate to ensure the amount applied is the minimum that provides therapeutic benefit.
Elderly: Clinical studies have not identified differences in responses between the elderly and younger patients. The greater frequency of decreased hepatic or renal function in the elderly may delay elimination if systemic absorption occurs. Therefore, the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.
Renal and Hepatic Impairment: In case of systemic absorption (when application is over a large surface area for a prolonged period) metabolism and elimination may be delayed therefore increasing the risk of systemic toxicity. Therefore, the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.
Administration: Due to inflammable nature of Betnovate lotion, patients should avoid smoking or being near an open flame during application and immediately after use.
Overdosage
Symptoms: Topically applied betamethasone valerate may be absorbed in sufficient amounts to produce systemic effects. Acute overdosage is very unlikely to occur, however, in the case of chronic overdosage or misuse the features of hypercortisolism may occur (see Adverse Effects).
Treatment: In the event of overdose, Betnovate should be withdrawn gradually by reducing the frequency of application, or by substituting a less potent corticosteroid because of the risk of glucocorticosteroid insufficiency.
Further management should be as clinically indicated or as recommended by the National Poisons Center, where available.
Treatment: In the event of overdose, Betnovate should be withdrawn gradually by reducing the frequency of application, or by substituting a less potent corticosteroid because of the risk of glucocorticosteroid insufficiency.
Further management should be as clinically indicated or as recommended by the National Poisons Center, where available.
Contraindications
The following conditions should not be treated with Betnovate: Untreated cutaneous infection, rosacea, acne vulgaris, pruritus without inflammation, perianal and genital pruritus and perioral dermatitis.
Use in children: Contraindicated in dermatoses in infants <1 year, including dermatitis.
Use in children: Contraindicated in dermatoses in infants <1 year, including dermatitis.
Special Precautions
Hypersensitivity to corticosteroids or to any of the excipients in the preparation. Local hypersensitivity reactions may resemble symptoms of the condition under treatment (see Adverse Reactions).
Manifestations of hypercortisolism (Cushing's syndrome) and reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, leading to glucocorticosteroid insufficiency, can occur in some individuals as a result of increased systemic absorption of topical steroids. If either of the previously mentioned are observed, withdraw the drug gradually by reducing the frequency of application, or by substituting a less potent corticosteroid. Abrupt withdrawal of treatment may result in glucocorticosteroid insufficiency (see Adverse Reactions).
Risk factors for increased systemic effects are: Potency and formulation of topical steroid, duration of exposure, application to a large surface area, use on occluded areas of skin eg, on intertriginous areas or under occlusive dressings (in infants the nappy may act as an occlusive dressing), increased hydration of the stratum corneum, use on thin skin areas eg, the face, use on broken skin or other conditions where the skin barrier may be impaired and in comparison with adults, children may absorb proportionally larger amounts of topical corticosteroids and thus, be more susceptible to systemic adverse effects. This is because children have an immature skin barrier and a greater surface area to body weight ratio compared with adults.
Infection Risk with Occlusion: Bacterial infection is encouraged by the warm, moist conditions induced by occlusive dressings and so the skin should be cleansed before a fresh dressing is applied.
Use in Psoriasis: Topical corticosteroids may be hazardous in psoriasis for a number of reasons including rebound relapses, development of tolerances, risk of generalized pustular psoriasis and development of local or systemic toxicity due to impaired barrier function of the skin have been reported in some cases. If used in psoriasis, careful patient supervision is important.
Application to the Face: Prolonged application to the face is undesirable as this area is more susceptible to atrophic changes.
Application to the Eyelids: If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye, as cataract and glaucoma might result from repeated exposure.
Concomitant Infection: Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions which have become infected. Any spread of infection requires withdrawal of topical corticosteroid therapy and administration of antimicrobial agents.
Chronic Leg Ulcers: Topical corticosteroids are sometimes used to treat the dermatitis around chronic leg ulcers. However, this use may be associated with a higher occurrence of local hypersensitivity reactions and an increased risk of local infection.
Effects on Ability to Drive or Operate Machinery: There have been no studies to investigate the effect of Betnovate on driving performance or the ability to operate machinery. A detrimental effect on such activities would not be anticipated from the adverse reaction profile of topical Betnovate.
Impairment of Fertility: There are no data in humans to evaluate the effect of topical corticosteroids on fertility.
Use in pregnancy: There are limited data from the use of Betnovate in pregnant women.
Topical administration of corticosteroids to pregnant animals can cause abnormalities of fetal development (see Pharmacology: Toxicology under Actions).
The relevance of this finding to human beings has not been established; however, administration of Betnovate during pregnancy should only be considered if the expected benefit to the mother outweighs the risk to the fetus. The minimum quantity should be used for the minimum duration.
Use in lactation: The safe use of topical corticosteroids during lactation has not been established. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable amounts in breast milk. Administration of Betnovate during lactation should only be considered if the expected benefit to the mother outweighs the risk to the infant. If used during lactation, Betnovate should not be applied to the breasts to avoid accidental ingestion by the infant.
Use in children: In infants and children <12 years, long-term continuous topical corticosteroid therapy should be avoided where possible, as adrenal suppression can occur.
Manifestations of hypercortisolism (Cushing's syndrome) and reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, leading to glucocorticosteroid insufficiency, can occur in some individuals as a result of increased systemic absorption of topical steroids. If either of the previously mentioned are observed, withdraw the drug gradually by reducing the frequency of application, or by substituting a less potent corticosteroid. Abrupt withdrawal of treatment may result in glucocorticosteroid insufficiency (see Adverse Reactions).
Risk factors for increased systemic effects are: Potency and formulation of topical steroid, duration of exposure, application to a large surface area, use on occluded areas of skin eg, on intertriginous areas or under occlusive dressings (in infants the nappy may act as an occlusive dressing), increased hydration of the stratum corneum, use on thin skin areas eg, the face, use on broken skin or other conditions where the skin barrier may be impaired and in comparison with adults, children may absorb proportionally larger amounts of topical corticosteroids and thus, be more susceptible to systemic adverse effects. This is because children have an immature skin barrier and a greater surface area to body weight ratio compared with adults.
Infection Risk with Occlusion: Bacterial infection is encouraged by the warm, moist conditions induced by occlusive dressings and so the skin should be cleansed before a fresh dressing is applied.
Use in Psoriasis: Topical corticosteroids may be hazardous in psoriasis for a number of reasons including rebound relapses, development of tolerances, risk of generalized pustular psoriasis and development of local or systemic toxicity due to impaired barrier function of the skin have been reported in some cases. If used in psoriasis, careful patient supervision is important.
Application to the Face: Prolonged application to the face is undesirable as this area is more susceptible to atrophic changes.
Application to the Eyelids: If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye, as cataract and glaucoma might result from repeated exposure.
Concomitant Infection: Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions which have become infected. Any spread of infection requires withdrawal of topical corticosteroid therapy and administration of antimicrobial agents.
Chronic Leg Ulcers: Topical corticosteroids are sometimes used to treat the dermatitis around chronic leg ulcers. However, this use may be associated with a higher occurrence of local hypersensitivity reactions and an increased risk of local infection.
Effects on Ability to Drive or Operate Machinery: There have been no studies to investigate the effect of Betnovate on driving performance or the ability to operate machinery. A detrimental effect on such activities would not be anticipated from the adverse reaction profile of topical Betnovate.
Impairment of Fertility: There are no data in humans to evaluate the effect of topical corticosteroids on fertility.
Use in pregnancy: There are limited data from the use of Betnovate in pregnant women.
Topical administration of corticosteroids to pregnant animals can cause abnormalities of fetal development (see Pharmacology: Toxicology under Actions).
The relevance of this finding to human beings has not been established; however, administration of Betnovate during pregnancy should only be considered if the expected benefit to the mother outweighs the risk to the fetus. The minimum quantity should be used for the minimum duration.
Use in lactation: The safe use of topical corticosteroids during lactation has not been established. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable amounts in breast milk. Administration of Betnovate during lactation should only be considered if the expected benefit to the mother outweighs the risk to the infant. If used during lactation, Betnovate should not be applied to the breasts to avoid accidental ingestion by the infant.
Use in children: In infants and children <12 years, long-term continuous topical corticosteroid therapy should be avoided where possible, as adrenal suppression can occur.
Use In Pregnancy & Lactation
Use in pregnancy: There are limited data from the use of Betnovate in pregnant women.
Topical administration of corticosteroids to pregnant animals can cause abnormalities of fetal development (see Pharmacology: Toxicology under Actions).
The relevance of this finding to human beings has not been established; however, administration of Betnovate during pregnancy should only be considered if the expected benefit to the mother outweighs the risk to the fetus. The minimum quantity should be used for the minimum duration.
Use in lactation: The safe use of topical corticosteroids during lactation has not been established. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable amounts in breast milk. Administration of Betnovate during lactation should only be considered if the expected benefit to the mother outweighs the risk to the infant. If used during lactation, Betnovate should not be applied to the breasts to avoid accidental ingestion by the infant.
Topical administration of corticosteroids to pregnant animals can cause abnormalities of fetal development (see Pharmacology: Toxicology under Actions).
The relevance of this finding to human beings has not been established; however, administration of Betnovate during pregnancy should only be considered if the expected benefit to the mother outweighs the risk to the fetus. The minimum quantity should be used for the minimum duration.
Use in lactation: The safe use of topical corticosteroids during lactation has not been established. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable amounts in breast milk. Administration of Betnovate during lactation should only be considered if the expected benefit to the mother outweighs the risk to the infant. If used during lactation, Betnovate should not be applied to the breasts to avoid accidental ingestion by the infant.
Adverse Reactions
Adverse drug reactions (ADRs) are listed as follows by MedDRA system organ class and by frequency. Frequencies are defined as: Very common (≥1/10); common (≥1/100 and <1/10); uncommon (≥1/1000 and<1/100); rare (≥1/10,000 and <1/1000); very rare (<1/10,000), including isolated reports.
Post-Marketing Data: Infections and Infestations: Very Rare: Opportunistic infection.
Immune System Disorders: Very Rare: Local hypersensitivity.
Endocrine Disorders: Very Rare: Hypothalmic-pituitary adrenal (HPA) axis suppression, Cushingoid features (eg, moon face, central obesity), delayed weight gain/growth retardation in children, osteoporosis, glaucoma, hyperglycemia/glucosuria, cataract, hypertension, increased weight/obesity, decreased endogenous cortisol levels, alopecia, trichorrhexis.
Skin and Subcutaneous Tissue Disorders: Common: Pruritus, local skin burning/skin pain. Very Rare: Allergic contact dermatitis/dermatitis, erythema, rash, urticaria, pustular psoriasis, skin thinning*/skin atrophy*, skin wrinkling*, skin dryness*, striae*, telangiectasias*, pigmentation changes, hypertrichosis, exacerbation of underlying symptoms.
General Disorders and Administration Site Conditions: Very Rare: Application site irritation/pain.
*Skin features secondary to local and/or systemic effects of HPA axis suppression.
Post-Marketing Data: Infections and Infestations: Very Rare: Opportunistic infection.
Immune System Disorders: Very Rare: Local hypersensitivity.
Endocrine Disorders: Very Rare: Hypothalmic-pituitary adrenal (HPA) axis suppression, Cushingoid features (eg, moon face, central obesity), delayed weight gain/growth retardation in children, osteoporosis, glaucoma, hyperglycemia/glucosuria, cataract, hypertension, increased weight/obesity, decreased endogenous cortisol levels, alopecia, trichorrhexis.
Skin and Subcutaneous Tissue Disorders: Common: Pruritus, local skin burning/skin pain. Very Rare: Allergic contact dermatitis/dermatitis, erythema, rash, urticaria, pustular psoriasis, skin thinning*/skin atrophy*, skin wrinkling*, skin dryness*, striae*, telangiectasias*, pigmentation changes, hypertrichosis, exacerbation of underlying symptoms.
General Disorders and Administration Site Conditions: Very Rare: Application site irritation/pain.
*Skin features secondary to local and/or systemic effects of HPA axis suppression.
Drug Interactions
Co-administered drugs that can inhibit CYP3A4 (eg, ritonavir, itraconazole) have been shown to inhibit the metabolism of corticosteroids leading to increased systemic exposure. The extent to which this interaction is clinically relevant depends on the dose and route of administration of the corticosteroids and the potency of the CYP3A4 inhibitor.
Incompatibilities: No incompatibilities have been identified.
Incompatibilities: No incompatibilities have been identified.
Storage
Store below 30°C. Contents are flammable. Keep away from fine, flame or heat. Protect from light or direct sunlight.
Action
Pharmacotherapeutic Group: Potent corticosteroids (group III). ATC Code: D07AC.
Pharmacology: Mechanism of Action: Topical corticosteroids act as anti-inflammatory agents via multiple mechanisms to inhibit late phase allergic reactions including decreasing the density of mast cells, decreasing chemotaxis and activation of eosinophils, decreasing cytokine production by lymphocytes, monocytes, mast cells and eosinophils, and inhibiting the metabolism of arachidonic acid.
Pharmacodynamic Effect: Topical corticosteroids have anti-inflammatory, antipruritic and vasoconstrictive properties.
Pharmacokinetics: Absorption: Topical corticosteroids can be systemically absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.
Distribution: The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids is necessary because circulating levels are well below the level of detection.
Metabolism: Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. They are metabolised, primarily in the liver.
Elimination: Topical corticosteroids are excreted by the kidneys. In addition, some corticosteroids and their metabolites are also excreted in the bile.
Toxicology: Preclinical Safety Data: Carcinogenicity: Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone valerate.
Genotoxicity: No specific studies have been conducted to investigate the genotoxic potential of betamethasone valerate.
Impairment of Fertility: The effect on fertility of betamethasone valerate has not been evaluated in animals.
Pregnancy: Subcutaneous administration of betamethasone valerate to mice or rats at doses ≥0.1 mg/kg/day or rabbits at doses ≥12 mcg/kg/day during pregnancy produced fetal abnormalities including cleft palate.
Pharmacology: Mechanism of Action: Topical corticosteroids act as anti-inflammatory agents via multiple mechanisms to inhibit late phase allergic reactions including decreasing the density of mast cells, decreasing chemotaxis and activation of eosinophils, decreasing cytokine production by lymphocytes, monocytes, mast cells and eosinophils, and inhibiting the metabolism of arachidonic acid.
Pharmacodynamic Effect: Topical corticosteroids have anti-inflammatory, antipruritic and vasoconstrictive properties.
Pharmacokinetics: Absorption: Topical corticosteroids can be systemically absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.
Distribution: The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids is necessary because circulating levels are well below the level of detection.
Metabolism: Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. They are metabolised, primarily in the liver.
Elimination: Topical corticosteroids are excreted by the kidneys. In addition, some corticosteroids and their metabolites are also excreted in the bile.
Toxicology: Preclinical Safety Data: Carcinogenicity: Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone valerate.
Genotoxicity: No specific studies have been conducted to investigate the genotoxic potential of betamethasone valerate.
Impairment of Fertility: The effect on fertility of betamethasone valerate has not been evaluated in animals.
Pregnancy: Subcutaneous administration of betamethasone valerate to mice or rats at doses ≥0.1 mg/kg/day or rabbits at doses ≥12 mcg/kg/day during pregnancy produced fetal abnormalities including cleft palate.
MedsGo Class
Topical Corticosteroids
Features
Brand
Betnovate
Full Details
Dosage Strength
1mg /ml
Drug Ingredients
- Betamethasone
Drug Packaging
Lotion 20ml
Generic Name
Betamethasone Valerate
Dosage Form
lotion
Registration Number
DR-X1716
Drug Classification
Prescription Drug (RX)
Please sign in so that we can notify you about a reply